165 related articles for article (PubMed ID: 21553278)
1. The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series.
Moghimi J; Sheikhvatan M; Semnani V
Rheumatol Int; 2012 Aug; 32(8):2271-4. PubMed ID: 21553278
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF-alpha therapy for ankylosing spondylitis.
Son JH; Cha SW
Clin Orthop Surg; 2010 Mar; 2(1):28-33. PubMed ID: 20190998
[TBL] [Abstract][Full Text] [Related]
3. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
[TBL] [Abstract][Full Text] [Related]
4. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
[TBL] [Abstract][Full Text] [Related]
5. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
6. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH
J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
[TBL] [Abstract][Full Text] [Related]
7. Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population.
Lian F; Yang X; Liang L; Xu H; Zhan Z; Qiu Q; Ye Y
Rheumatol Int; 2012 Jun; 32(6):1663-7. PubMed ID: 21387110
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
9. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis.
Martín-Mola E; Sieper J; Leirisalo-Repo M; Dijkmans BA; Vlahos B; Pedersen R; Koenig AS; Freundlich B
Clin Exp Rheumatol; 2010; 28(2):238-45. PubMed ID: 20483046
[TBL] [Abstract][Full Text] [Related]
10. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of etanercept for treating ankylosing spondylitis].
Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
13. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.
Giardina AR; Ferrante A; Ciccia F; Impastato R; Miceli MC; Principato A; Triolo G
Rheumatol Int; 2010 Sep; 30(11):1437-40. PubMed ID: 19851772
[TBL] [Abstract][Full Text] [Related]
14. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
15. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients.
Lee SH; Lee YA; Hong SJ; Yang HI
Clin Rheumatol; 2008 Feb; 27(2):179-81. PubMed ID: 17874173
[TBL] [Abstract][Full Text] [Related]
16. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
17. Etanercept: new indication. For ankylosing spondylitis: another option.
Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ultrasound-guided local injections of etanercept into entheses of ankylosing spondylitis patients with refractory Achilles enthesitis.
Huang Z; Cao J; Li T; Zheng B; Wang M; Zheng R
Clin Exp Rheumatol; 2011; 29(4):642-9. PubMed ID: 21906429
[TBL] [Abstract][Full Text] [Related]
19. Results from an open-label extension study of etanercept in ankylosing spondylitis.
Davis J; Webb A; Lund S; Sack K
Arthritis Rheum; 2004 Apr; 51(2):302-4. PubMed ID: 15077279
[No Abstract] [Full Text] [Related]
20. Etanercept therapy in Behçet's disease. The tight control strategy in refractory disease.
Mohammed RH
Z Rheumatol; 2014 Sep; 73(7):650-6. PubMed ID: 24549921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
